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The rupestines, a family of guaipyridine alkaloids, are isolated from the plant Artemisia 
rupestris. Historically, this plant was used in traditional Chinese medicine due to its reported 
antitumor, antibacterial, and antiviral activities as well as reported protection of the liver. The 
rupestines can only be isolated from their parent plant in small quantities, making the total 
synthesis of these guaipyridine alkaloids of particular interest. Cananodine, another guaipyridine 
alkaloid, is a biologically active compound that can be isolated in small quantities from the fruits 
of Cananga odorata and displays activity against two types of hepatocellular carcinoma cell lines. 
It is hypothesized that the rupestines may also have anticancer activity. Synthesis of the rupestines 
would allow biological testing to determine if they, like cananodine, contain any activity against 
liver cancer or other types of cancer. In this project, the total synthesis of rupestines B and C was 
accomplished. 
The cyclic guaipyridine core in the synthesis of rupestines B and C was formed via 
intramolecular Mizoroki-Heck cyclization. In the first generation synthesis of rupestines B and C, 
a ketoester intermediate underwent an undesired decarbonylation while producing only trace 
amounts of the desired product. To avoid the decarbonylation of the ketone, the starting material 
was changed such that a decarboxylation of an allyl ester would be favored. Alkylation of allyl 3-
oxopentanoate with a substituted picolyl bromide provided the carbon-backbone of the target. 
Treatment of a diallyl protected intermediate with palladium(0) in basic methanol resulted in the 
cleavage of both allyl groups and in situ decarboxylation of the intermediate keto acid. Triflation 
of the resulting phenolic hydroxyl gave the cyclization precursor. Exposure of the triflate to 
palladium(0) in hot basic dioxane resulted in an intramolecular Mizoroki-Heck reaction that 




exocyclic alkene gave rupestines B and C in quantitative yield as a 1:2 mixture of diastereomers. 
While these diastereomers were not separable using flash column or radial chromatography, they 
were separable using reverse phase MPLC. The 1H and 13C spectra for each diastereomer were 
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1. Introduction  
 
1.1. Hepatocellular carcinoma 
 
Hepatocellular carcinoma (HCC) is a liver cancer responsible for more than 12,000 deaths 
a year in the U.S. and is the most common type of primary liver cancer in adults.1 Diagnosis of 
HCC has tripled in the U.S. over the last four decades, and there are approximately 700,000 deaths 
each year worldwide.2 HCC is an aggressive cancer which occurs most frequently in patients with 
cirrhosis, a disease which occurs when damaged liver cells are replaced with scar tissue. The 
scarring that results from cirrhosis can be brought on by viral infections hepatitis B and C, alcohol 
abuse, and sometimes hemochromatosis (an excess of iron stored in the liver).3 Treatment of HCC 
is largely dependent on the stage and progression of the cancer when diagnosed. Only about one 
third of patients diagnosed with HCC have enough liver function to be considered for curative 
treatments.4 These treatments include surgical resection, liver transplantation or occasionally 
tumor ablation. Most chemotherapy and other forms of common cancer treatments have proven to 
be unsuccessful in treating HCC. If the cancer is diagnosed before it has spread to surrounding 
areas, the 5-year survival rate is 31%, but once the disease has metastasized this survival rate drops 
to 11%.5,6 Transplantation is considered to be the most successful treatment for HCC patients, but 
is limited by the low availability of donor organs and the number of patients who are good surgical 
candidates. For patients of liver resection, the 5-year survival rate is 25-50% with a high rate of 
recurrence.7,8 Survival time for those who are not candidates for curative treatments can be as low 
as six weeks, with death typically occurring within six months from the time of diagnosis. 
Understanding the cancer and how it behaves molecularly may provide drug-based designs for the 





1.2. Current treatments of HCC 
 
Protein kinases (PKs) are enzymes responsible for modulating the activity of proteins by 
phosphorylation. PKs play a role in cancer initiation and growth, making kinase inhibitors of 
particular interest in cancer treatment studies. Kinase inhibitors are divided into type I and type II 
based on their binding modes. Type I kinase inhibitors bind to the active conformation of the 
enzyme and function by occupying the active site, preventing it from binding to an ATP molecule. 
Type II kinase inhibitors bind to the inactive form of the kinase, preventing it from returning to 
the active conformation.9 
While there are currently 35 approved kinase inhibitors for the treatment of various 
cancers, only four are for the treatment of HCC. Sorafenib [Nexavar® (1.1)], approved by the FDA 
in 2007, has become the standard treatment for HCC.10 However, studies have shown that it is not 
widely used due to the high treatment costs ($15,000/month) and its ability to only extend the life 
of patients by about 3 months when compared to placebo.11 Regorafenib [Stivarga® (1.2)], a 
derivative of sorafenib, has been shown to improve mean survival time by 10.6 months versus 7.8 




Sorafenib has a reported IC50 value of 4.5 𝜇M against the HepG2 HCC cell line and inhibits 
B-Raf and C-Raf PKs in the phosphorylation pathway.13 Specific structural characteristics of 





























cysteine 531 residue of B-Raf kinase interacts with these inhibitors through strong hydrogen 
bonding (Figure 1). In the cysteine 531 residue, the hydrogen of the amide binds to the pyridine 
nitrogen atom while the carbonyl binds to the hydrogen of the amide group (3.0 Å and 3.2 Å, 
respectively), in addition to hydrogen bonds of the other residues to the diaryl urea moiety (not 
shown).14 Pyridine groups contained in the ‘head’ moiety exist in several type II kinase inhibitors. 
These pyridine groups participate in hydrogen bonds with residues in the activation loop, 





Figure 1. Hydrogen bonding between sorafenib/regorafenib and B-Raf kinase. 
 
 
More recently, a drug called cabozantinib [Cabometyx® (1.4)] was approved for treatment 
of HCC if treatment with sorafenib is ineffective.16,17 A fourth multi-kinase inhibitor, lenvatinib 
[Lenvima® (1.5)]18,19 was also recently approved by the FDA and shown to have similar effects to 
















































1.3. Discovery of (+)-cananodine and the rupestine natural products 
Cananga odorata, also known as the ylang-ylang tree, is a member of the Annonaceae 
family that has been used in traditional Taiwanese medicine.22 This tropical tree is native to India, 
Malaysia, and the Philippines and can grow up to 12 meters in height in an ideal climate. The 
leaves and flowers of the ylang-ylang tree can be distilled to produce the popular essential oil often 
used in perfumes and aromatherapy.23 
Cananodine, a biologically active guaipyridine alkaloid, shown to have activity against 
certain HCC cell lines, was originally discovered by Wu et al when they isolated and characterized 
eight alkaloids and sesquiterpenes from the fruits of C. odorata (Figure 2).24 The guaipyridine 
alkaloids are a family of compounds that all share an unusual carbon structure of a pyridine ring 
fused to a seven-membered carbocycle. Cananodine also contains the pyridine head group moiety 
that is found in type II kinase inhibitors like sorafenib and regorafenib. In addition to (+)-
cananodine (1.6), the other compounds isolated were the eudesmanes cryptomerediol 11-𝛼-L-
rhamnoside (1.7), 𝛾-eudesmol (1.8), 𝛾-eudesmol 11-𝛼-rhamnoside (1.9), and alkaloids 









Figure 2. Compounds isolated from the fruits of C. odorata. 
 
 
While cananodine can be isolated from the fruits of C. odorata, 3.5 kg of fruit are required 
to obtain only 10 mg of the biologically active molecule. Cananodine is the most potent of the 
compounds extracted, containing inhibition against HepG2 and Hep2,2,15 HCC cell lines with 
IC50 values of 0.22 and 3.8 µg/mL, respectively.25 Due to the greater in vitro potency against Hep 
G2 cell lines when compared to sorafenib, cananodine has the potential of being a more effective 
line of treatment for HCC. The inhibition of B-Raf kinase with cananodine is hypothesized to be 
similar to that of sorafenib and regorafenib, where the pyridyl nitrogen and alcohol hydrogen bond 
to the amide groups in the cysteine 531 residue (Figure 3). Two total syntheses of cananodine have 
been reported to date, the first by Craig and Henry in 2006 and the second from the Vyvyan lab in 






























1.6 1.7 R = H
1.7a R = Ac
1.8 1.9







Figure 3. Hypothetical hydrogen bonding between cananodine and B-Raf kinase. 
 
 
The rupestines (Figure 4), a family of guaipyridine alkaloids, can be isolated from the plant 
Artemisia rupestris, more commonly known as rock wormwood. The bicyclic core of the 
rupestines is similar to that of cananodine, which suggests the rupestines may also contain 
inhibitory activity against HCC. Historically, this plant has been implemented in traditional 
Chinese medicine and has reported antitumor, antibacterial, and antiviral activities as well as 
reported protection of the liver. Aisa et al discovered the twelve new guaipyridine alkaloids, 
rupestines A-D and F-M (1.15-1.26) in 2010 and 2012.28 The rupestines and cananodine share a 
similar bicyclic core, only varying in the substituent at the 8-position of the seven-membered ring 
as well as the stereochemistry at the 5- and 8-positions. Due to the structural similarities, it is 
reasonable to predict that the rupestines may possess similar cytotoxicity to that of cananodine. 
While not all of the rupestines contain a hydrogen bond donor in the substituent at the 8-position, 
it is hypothesized that the substituent might still act as a hydrogen bond acceptor or have the ability 
to hydrogen bond to other amino acid residues in the activation loop. Developing a synthetic source 
of these compounds would allow for testing of anticancer activity and the possibility to establish 
these molecules as potential HCC treatments. Like cananodine, the rupestines can only be isolated 
from their parent plant in small quantities, making the total synthesis of these guaipyridine 


















Figure 4. Rupestines A-D, F-M. 
 
1.4. Previous syntheses of guaipyridine alkaloids 
The first syntheses of guaipyridine alkaloids were reported in 1966 by Büchi et al.29 They 
isolated two alkaloids from the essential oil extract of Pogostemon cablin (patchouli oil): 
patchoulipyridine (1.27) and epiguaipyridine (1.28) (Figure 5). To verify the structural 
configuration of these two alkaloids, Büchi synthesized them. Starting with 𝛽-patchoulene (1.29), 
hydrazoic acid was used to incorporate the nitrogen of the pyridine ring followed by a palladium 
catalyzed dehydrogenation to produce a mixture of compounds. This mixture was thought to 
include patchoulipyridine (1.27) as the physical properties were similar to that of the naturally 

















rupestine L !-Me 1.25
rupestine M β-Me 1.26
rupestine J 1.23
rupestine H β-Me 1.21
rupestine I !-Me 1.22
rupestine G 1.20rupestine F 1.19
rupestine D 1.18rupestine B !-Me 1.16








initial reduction of the hydroxyl group followed by treatment with hydrazoic acid to incorporate 
the nitrogen atom. This also provided dihydroepiguaipyridine (1.31) which was used to correlate 





Figure 5. Compounds from Büchi and van der Gen isolations and syntheses. 
 
 
In 1972, van der Gen et al found that the absolute configuration of synthetic 1.31 by Büchi 
et al was not consistent with the configuration of the isolated natural product.30 Guaiol (1.30) has 
established stereochemistry of 7R, 10S, yet Büchi et al assigned a 7R, 10R stereochemistry to the 
naturally isolated product. To confirm the stereochemistry, van der Gen produced syntheses 
involving starting materials with known configurations to produce both C10 epimers.  
To produce the 10S epimer, guaiol (1.30) was subjected to a palladium-catalyzed alkene 
isomerization with subsequent ozonolysis to provide diketone 1.32. Treatment of diketone 1.32 
with hydroxylamine hydrochloride in ethanol resulted in cyclization to establish the pyridine ring. 
Under these conditions, the tertiary alcohol is dehydrated to provide the 10S epimer (1.34) with 
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starting material to synthesize the 10R epimer with a similar reaction sequence as the 10S epimer. 
The 10R epimer was obtained in a mixture of products and had differing spectral properties, 
confirming that Büchi had incorrectly assigned the stereochemistry and had actually produced the 
dihydro C10 epimer of 1.28, guaipyridine (1.34).  
In 1987, two new syntheses of compounds 1.28 and 1.34 were produced by Okatani and 
Koyama et al. In the first route, they implemented an inverse electron demand Diels-Alder reaction 
of electron-deficient 1,2,3-triazene with electron-rich enamines (Scheme 1).31 The enamine 
isomers 1.36 and 1.37 were synthesized from 3-isopropenyl-1,6-methylcycloheptanone (1.35). 
Once treated with triazine, the Diels-Alder reaction produced three compounds which were 
isolated by HPLC (high performance liquid chromatography): 1.28, 1.34, and 1.38. A second 
method was discovered where treatment of 1.35 with O-(𝛼-methylallyl)hydroxylamine provided 
oxime 1.39, followed with thermal decomposition gave compounds 1.28, 1.34, 1.40 and 1.41 as a 
mixture (Scheme 2).32 
 






































While these studies provide useful information on the syntheses of guaipyridine alkaloids, 
they are not very practical. The routes developed by Büchi and van der Gen involve novel 
reactions, but require the naturally occurring starting materials that already possess the seven-
membered carbocycle. These materials are difficult to obtain and can only be sourced in small 
quantities. Additionally, none of these routes are regioselective or stereoselective and 
stereochemistry is often important to a compound’s cytotoxicity when used medicinally.  
 
 
1.5. Previous syntheses of (+)-cananodine and its epimer 
The first synthesis of cananodine (1.6) was reported by Craig and Henry in 2006.26 They 
accomplished the total synthesis in a yield of 4% while implementing chiral auxiliaries to set the 
stereochemistry. Their synthesis began with an addition of bromide 1.43 to the lithium enolate of 
1.42, providing the 1,7-diene 1.44 (Scheme 3). Cycloheptane 1.46 was formed via a ring-closing 
olefin metathesis (RCM) promoted by Grubbs’ second-generation catalyst. When cycloheptane 
1.46 was exposed to desilylation conditions (both acidic and basic), significant decomposition 
occurred. To circumvent this issue, they reversed the order of the RCM and the desilylation steps. 
Treatment of 1,7-diene 1.44 with HCl and reaction of the resulting allylic alcohol 1.45 with 
Grubbs’ catalyst produced alcohol 1.47. Removal of the chiral auxiliary was accomplished 
followed by esterification of the primary alcohol with 4-methyl-2-(4-tolylsulfonyl)-4-pentenoic 
acid to give alkene 1.48. Substrate 1.48 underwent a decarboxylative Claisen rearrangement under 
microwave-irradiation conditions to provide the 1,6-diene 1.49 as a mixture of two of the four 
possible diastereomers. Formation of pyridine 1.50 is accomplished by ozonolysis of 1,6-diene 
1.49, ammonolysis to form the pyridine ring, and finally reaction with methyl-magnesium bromide 










A second synthesis of cananodine was reported in 2017 by Vyvyan et al.27 This total 
synthesis involved an intramolecular epoxide opening to establish the bicyclic ring system 
(Scheme 4). The first reaction involved a palladium catalyzed coupling of pyridyl iodide 1.51 with 
pinacol boronate 1.52 to give pyridyl diene 1.53 that was subjected to AD-mix 𝛼	to provide diol 
1.54. The diol was converted to epoxide 1.55 using mesyl chloride and basic methanol. 
Deprotonation at the picolyl position with n-butyllithium at -78 °C promoted the intramolecular 
epoxide opening of 1.55 to give the seven-membered carbocycle of alkene 1.56. In the final step, 
the exocyclic alkene was hydrogenated using hydrogen gas with Wilkinson’s catalyst to give (+)-











1.44: R = TBDPS






1.46: R = TBDPS


























































The synthesis of ent-cananodine was also accomplished by Vyvyan et al. Intermediate 1.53 
was subjected to AD-mix 𝛽 to provide diol 1.58, followed by epoxidation to give epoxide 1.59 
(Scheme 5). The seven-membered carbocycle was formed by again using n-butyllithium at -78 °C 
to provide alkene 1.60 which was then hydrogenated with hydrogen gas and Wilkinson’s catalyst 
to give ent-cananodine (1.61) and its epimer (1.62).  
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Both syntheses by Vyvyan et al contain weaknesses that impact the overall yield as well 
as the selectivity to produce the desired products. In the intramolecular epoxide opening step, 
deprotonation at the picolyl position is non-selective and can occur on both methyl groups at the 
2- and 6-positions. This results in yields of 33% and 35% for the synthesis of cananodine and ent-
cananodine, respectively, assuming irreversible deprotonation. If deprotonation occurs at the 6-
position, the epoxide will not open and the cyclization will not occur, which could lead to an 
undesired side product. Also, the hydrogenation step is non-diastereoselective, most likely because 
the tertiary alcohol is too far from the alkene to direct the hydrogenation into the lowest energy 
conformation. The diastereomers were unable to be separated by either normal-phase or reverse-

















1.6. Previous rupestine synthesis 
 In 2018, Huang et al published a total synthesis of rupestine G and its diastereomers 
(1.72).33 The synthesis was accomplished by a key Suzuki reaction followed by a ring-closing 
metathesis in a sequence of nine linear steps with an overall yield of 18.9% (Scheme 6). 
 






  The cyanopyridine 1.65 was prepared by oxidation of bromide 1.63 with m-CPBA 
followed by a modified Reissert-Henze34 reaction. Compound 1.66 was obtained by a 
decarboxylative Blaise reaction with potassium methyl malonate.35 Allyl bromide in basic ethanol 





































































reaction, treatment of substrate 1.67 with isopropenylboronic acid pinacol ester gave diene 1.68 in 
a 92% yield. The RCM catalyzed by Grubbs’ second-generation catalyst was carried out to provide 
alcohol 1.69 followed by a reduction using NaBH4 to give alcohol 1.70. Mesyl chloride was used 
for the dehydration of alcohol 1.70 to give the diene product 1.71, which was subsequently non-
selectively hydrogenated using Pd/C to provide rupestine G as a mixture of diastereomers in an 
overall yield of 91.4%. The components of the mixture were isolated first by preparative TLC to 
provide two pairs of diastereoisomers which were further separated using preparative chiral HPLC 
to give the four optically pure isomers.  
 While all the previously mentioned syntheses of guaipyridine alkaloids provide advances, 
they are either completely non-selective or low yielding. These synthetic flaws prevent the routes 
from being commercially practical and therefore limit their feasibility for use as potential 
treatments. A new synthetic approach toward the guaipyridines is needed to prepare sufficient 
quantities of these compounds for biological testing and application. With new syntheses of 
guaipyridine alkaloids that are both selective as well as commercially practical, a new class of 














2. First generation strategy for the synthesis of rupestines B and C  
 
2.1. Original Synthetic Strategy  
 
In our original retrosynthetic analysis of rupestines B (1.16) and C (1.17), we planned to 
form the target compounds as a mixture of optically pure diastereomers that we would separate in 
the final step (Scheme 7). The final steps to accessing rupestines B and C were to be a 
hydrogenation of the conjugated 1,1-disubstituted alkene and an acid catalyzed hydrolysis of the 
methyl ester. The seven-membered carbocycle would be accessed from triflate 2.1 through a key 
intramolecular Mizoroki-Heck reaction. Triflate 2.1 would be prepared from allyl ether 2.2 by 
deallylation and triflation of the resulting aryl hydroxyl. Intermediate 2.2 would be prepared from 
methyl 3-oxopentanoate (2.3) and picolyl bromide 2.4 through alkylation of an enolate.36 
 




We began by alkylating commercially available methyl 3-oxopentanoate (2.3) with picolyl 
bromide 2.4, which occurs through an SN2 reaction, to give keto ester 2.5 in nearly quantitative 





























2.2. This second alkylation step proved rather difficult due to the steric hindrance involved in 
forming the quaternary carbon center. We tried various conditions which involved changing the 
base, solvent and temperature (see Table 1). The most successful alkylation conditions proved to 
be LHMDS in a solvent mixture of 5:1 THF:DMPU at reflux.37 The yield of allyl ether 2.2 under 
these conditions ranged from 20-60%, with most of the unreacted keto ester 2.5 being recovered 
through flash column chromatography.  
 





2.1.1. 4-Iodo-1-butene alkylation optimization 
 
 In the beginning of our synthetic studies, our original conditions for the second alkylation 
step with 4-iodo-1-butene (2.6) involved potassium tert-butoxide as a base in THF with reflux 
(Table 1, Entry 1). While these conditions afforded a consistent yield of 30%, the purification by 
flash column chromatography proved quite challenging and provided no recovered keto ester 2.5. 
In an effort to optimize these conditions in hope of increasing the yield and ease of purification, 
we explored various conditions. First, we altered our original conditions with additives such as 
crown ethers and DMPU (Entries 2,3). In both cases, the additives decreased the yield. We then 
changed the solvent from THF to dioxane to determine whether an increase in reflux temperature 


























was observed and no unreacted keto ester 2.5 was able to be recovered. NaH and LHMDS as 
potential bases were also studied (Entries 5-7). NaH in DMF gave no desired product, but LHMDS 
in THF gave similar results to our original alkylation conditions. To test the effect an additive 
would have on these conditions, we added DMPU to the reaction in a ratio of 5:1 THF:DMPU. 
While these conditions provided an inconsistent yield (25-60%), the reaction would occasionally 
result in greater product formation than our original conditions. Another benefit is the purification 
proved to be much simpler and the unreacted keto ester 2.5 starting material can be recovered 
almost completely by column chromatography. The variation in yields of the alkylation may be 
due to the volatility of the 4-iodo-1-butene (2.6) and its tendency to decompose over time.  
 
Table 1. Alkylation conditions study.  
Entry Base Solvent Temperature (°C) Additive 
Yield 
(%) 
1 t-BuOK THF 80 - 30 
2 t-BuOK THF 80 18-C-6 25 
3 t-BuOK THF 80 DMPU 16 
4 t-BuOK dioxane 120 - 0 
5 NaH DMF 100 - 0 
6 LHMDS THF  80 - 30 
7 LHMDS THF  80 DMPU 25-60 
 
 
In another effort to increase the yield of the alkylation step with 4-iodo-1-butene (2.6) , we 
thought to experiment with other leaving groups using our original conditions. We found that by 
replacing the iodide with a tosyl group (2.7), the yield remained the same and the reaction showed 









2.1.2. Decarbonylation of the ethyl ketone  
We then planned to cleave the allyl ether group of 2.2 to provide the phenolic hydroxyl of 
2.9, which would then be converted to the corresponding aryl triflate 2.1, setting the stage for an 
intramolecular Mizorki-Heck reaction. Unfortunately, when allyl ether 2.2 was exposed to 
palladium(0) in methanolic potassium carbonate, the ethyl ketone was cleaved as well, producing 
ester 2.8, while only trace amounts of alcohol 2.9 were observed in the 1H NMR spectrum (Scheme 
9).38,39 
 





The proposed mechanism for the decarbonylation begins with the reaction of potassium 
carbonate and methanol to form potassium bicarbonate and potassium methoxide (Scheme 10). 






























tetrahedral intermediate 2.10. The electron withdrawing ester then allows for cleavage of the 
carbon-carbon bond to form the resonance-stabilized enolate 2.11. The enolate is then protonated 
and the ester is reestablished to provide ester 2.12 along with methyl propionate (2.13). Ester 2.12 
also undergoes typical allyl cleavage of the aryl allyl ester with palladium as a catalyst to give the 
undesired product 2.8. The decarbonylation will also occur without the presence of the palladium 
catalyst, confirming the proposed mechanism. Using basic methanol as a method to cleave 
carbonyls of beta-keto esters is known, but typically occurs at higher temperatures.38 
 






2.1.3. Protecting group exploration  
 
 We attempted the synthesis with a methoxymethyl ether (MOM) protecting group on the 
aryl hydroxyl, hoping the ethyl ketone would remain intact during deprotection of the MOM group. 
MOM ethers are popular protecting groups for phenolic hydroxyls due to the typical ease of which 
































protic solvents by acids such as HCl40 or p-toluenesulfonic acid41 or by Lewis acids such as 
LiBF4.42 One such example involves the selective deprotection of MOM ethers to the 
corresponding phenol using carbon tetrabromide and triphenylphosphine in dichloroethane by 
Peng et al (Equation 2).43 
 
Equation 2.  
 
 
We began our study by protecting the phenolic type hydroxyl of 2.14 with MOM chloride 
(2.15) to give alcohol 2.16 followed by halogenation with N-bromosuccinimide to convert the 
primary alcohol to bromide 2.17 (Scheme 11). Alkylation with methyl 3-oxopentanoate (2.3) and 
picolyl bromide 2.17 gave keto ester 2.18 in decent yield. The second alkylation step with 4-iodo-
1-butene (2.6) gave substituted keto ester 2.19, but subsequent deprotection of the MOM group 
was unsuccessful. Many conditions were explored such as HCl, p-TSA, and LiCl but unreacted 
keto ester 2.19 was recovered quantitatively each time. Due to the difficulties with the 








MOMO R HO R
CBr4, PPh3
DCE, 40 ºC
R = NO2  92%
R = Br      91%
R = OBn  90%








We also attempted triflation of diol 2.14 to avoid the need for a later deprotection step 
altogether. The double triflation was successful but the resulting triflate was prone to severe 





















































3. Second generation strategy: Double deprotection  
 
3.1. Total synthesis of rupestines B and C 
 
Returning to our original synthetic scheme, we changed our starting material such that the 
ester would be cleaved at the same time as the deallylation of the phenolic hydroxyl, thereby 
preventing the decarbonylation of the ketone group. By changing methyl 3-oxopentanoate (2.3) to 
allyl 3-oxopentanoate (3.1), a double-deprotection would occur in situ to reveal the phenolic 
hydroxyl while keeping the ethyl ketone intact (Scheme 12). Triflation of the alcohol to give triflate 
3.3 would then set the stage for the intramolecular Mizoroki-Heck cyclization to form the seven-
membered ring system of the guaipyridines. The final step would be a hydrogenation of the 
exocyclic alkene to provide the target compounds as a mixture of diastereomers.  
 




Alkylation of allyl 3-oxopentanoate (3.1), prepared from keto ester 2.3 through 
transesterification with allyl alcohol,45 with picolyl bromide 2.4 provided intermediate 3.4 in 




























our optimized conditions provided keto ester 3.2. Treatment of keto ester 3.2 with palladium(0) in 
basic methanol resulted in the cleavage of both allyl groups and in situ decarboxylation of the 
intermediate keto acid to provide alcohol 3.5 (see Scheme 14). Since we were able to isolate 
alcohol 3.5 in a 97% yield, we concluded that the rate of reaction for the deallylation of the allyl 
ester is greater than that of the decarbonylation of the ethyl ketone, favoring the deallylation and 
in situ decarboxylation of the ester. Triflation of the resulting phenolic hydroxyl of alcohol 3.5 
gave the cyclization substrate 3.3. Exposure of triflate 3.3 to palladium(0) in hot basic dioxane 
resulted in an intramolecular Mizoroki-Heck reaction that formed the seven-membered carbocycle 
of 3.6 in satisfactory yield. Finally, hydrogenation of the exocyclic alkene gave rupestines B (1.16) 
and C (1.17) in quantitative yield as a 1:2 mixture of diastereomers.46 
 
 


























































 In the in situ decarboxylation of the intermediate keto-acid, the palladium catalyst 
coordinates to the alkene of keto ester 3.2, allowing the methoxide to attack the alkene terminus 
(Scheme 14). The alkene isomerizes and the carbon-oxygen bond is cleaved to produce 3-
methoxyprop-1-ene as a side product. The decarboxylation then occurs to produce CO2 and 
intermediate 3.7, which is then protonated at the beta-position to provide ethyl ketone 3.8. 
 
 






While the diastereomers 1.16 and 1.17 produced in the hydrogenation shown in Scheme 
13 were not separable using flash column or radial chromatography, we were able to separate them 
using reverse phase MPLC (medium pressure liquid chromatography). Taking clues from the 
literature describing the original isolation of the natural products, the first separation by MPLC 
was attempted with aqueous methanol. Over 20 minutes, the % methanol was increased gradually 
from 30% to 80% with a flow rate of 18 mL/min. To optimize the separation conditions, the flow 
rate, column loading and % methanol were all explored but the original conditions proved the most 
successful.  
In summary, rupestines B and C were prepared in six steps from allyl 3-oxopentanoate in 
a total yield of 9% and 18%, respectively. The 1H and 13C spectra for each diastereomer were 



















2-4).28 The resonances prove to be almost identical to those of the natural products, with the small 




Table 2. Rupestine B (1.16) 1H NMR Comparison.  
position Natural product (400 MHz) this work (300 MHz) 
H-C(3) 6.98 (d, J = 8) 6.97 (d, J = 9) 
H-C(4) 7.38 (d, J = 8) 7.36 (d, J = 9) 
H-C(5) 2.99-3.04 (m) 2.93-3.01 (m) 
Ha-C(6) 1.22-1.27 (m) 1.22-1.29 (m) 
Hb-C(6) 1.82-1.94 (m) 1.85-1.93 (m) 
Ha-C(7) 1.82-1.94 (m) 1.85-1.93 (m) 
Hb-C(7) 1.98-2.08 (m) 1.97-2.05 (m) 
H-C(8) 2.47-2.60 (m) 2.47-2.60 (m) 
Ha-C(9) 3.09 (d, J = 14) 3.06 (dt, J = 15, 9) 
Hb-C(9) 3.24 (dd, J = 14, 10.8) 3.24 (dd, J = 12, 9) 
CH2(13) or Me(13) 2.52 (q, J = 7.2) 2.53 (q, J = 9) 
Ha-C(14) or Me(14) 1.04 (t, J = 7.2) 1.05 (t, J = 6) 
Me(15) 2.51 (s) 2.49 (s) 




Table 3. Rupestine C (1.17) 1H NMR Comparison.  
position Natural product (400 MHz) this work (300 MHz) 
H-C(3) 6.94 (d, J = 7.6) 6.91 (d, J = 9) 
H-C(4) 7.33 (d, J = 7.6) 7.29 (d, J = 3) 
H-C(5) 2.95-3.04 (m) 2.96-3.04 (m) 
Ha-C(6) 1.72-1.88 (m) 1.72-1.88 (m) 
Ha-C(7) 1.72-1.88 (m) 1.72-1.88 (m) 
Hb-C(7) 2.00-2.10 (m) 1.97-2.10 (m) 
H-C(8) 2.67-2.75 (m) 2.67-2.72 (m) 
Ha-C(9) 3.16-3.24 (m) 3.19 (dd, J = 12, 18) 
Hb-C(9) 3.31-3.41 (m) 3.28-3.36 (m) 
CH2(13) or Me(13) 2.60 (q, J = 7.2) 2.56 (q, J = 9) 
Ha-C(14) or Me(14) 1.02 (t, J = 7.2) 1.02 (t, J = 9) 
Me(15) 2.50 (s) 2.46 (s) 















this work  
(75 MHz) 
1.17 
this work  
(75 MHz) 
C(2) 154.39 154.63 154.44 154.67 
C(3) 121.17 121.42 121.07 121.25 
C(4) 132.48 136.59 132.32 136.26 
C(5) 34.79 37.65 34.76 37.70 
C(6) 35.08 32.11 35.09 32.18 
C(7) 33.22 28.40 33.23 28.28 
C(8) 48.60 48.50 48.62 48.66 
C(9) 39.73 39.57 39.89 39.97 
C(10) 159.36 157.63 159.40 157.75 
C(11) 137.90 138.14 137.78 137.84 
C(12) 213.71 213.38 213.70 213.56 
C(13) 34.38 34.29 34.34 34.26 
C(14) 7.83 7.76 7.80 7.78 
C(15) 23.79 23.56 23.85 23.85 

















3.2. Intramolecular Mizoroki-Heck cyclization  
 
The well-established Mizoroki-Heck reaction is the reaction of an alkene with an 
unsaturated halide or triflate in the presence of base and a palladium catalyst. This reaction was 
the first carbon-carbon bond formation reaction to follow a Pd(0)/Pd(II) catalytic cycle, a reaction 
that earned Richard F. Heck a share of the 2010 Nobel Prize in Chemistry. Mizoroki et al was the 
first to report the palladium catalyzed reaction between olefins and aryl halides through vinylic 
hydrogen substitutions in 1971.47 Shortly after, Heck et al independently discovered and developed 
new reaction conditions that differed in the catalyst used, catalyst loading, base used, and lack of 
a solvent.48 
The method used to access the guaipyridine core centers around the intramolecular 
Mizoroki-Heck cyclization between a side-chain terminal alkene and an aryl triflate. The reaction 
involves organopalladium intermediates, where the palladium(0) intermediate is required. In the 
Mizoroki-Heck cyclization involving our specific substrates, we use 
tetrakis(triphenylphosphine)palladium(0) as our palladium source, which is converted to 
bis(triphenylphosphine)palladium(0) in situ. The first step in the catalytic cycle is an oxidative 
addition where the palladium complex inserts itself in the aryl-triflate bond (Scheme 15). The 
palladium then coordinates to the terminal alkene and the palladium undergoes migratory insertion 
into the alkene to form the seven-membered carbocycle. The next step involves a beta-hydride 
elimination to form the exocyclic alkene and the eliminated Pd-H species. In the last step, a 















It was not until 1979 that the first intramolecular Mizoroki-Heck reaction was reported. 
The first instances of the reaction were reported by Heck and expanded upon by Shibasaki.49,50 
This method has gained popularity in the field of total synthesis for its reliability to 
enantioselectively form carbon-carbon bonds. Overman and Dounay compiled extensive 
applications of the intramolecular Mizoroki-Heck reaction used in natural product synthesis, 
including the synthesis of terpenoids, polyketides, and alkaloids.51 A majority of Mizoroki-Heck 
cyclizations involve the formation of 5- or 6-membered rings, with only a few publications 




































formation of 7-membered carbocycles using palladium/imidazolinium salt protocols for 
intramolecular Mizoroki-Heck reactions, accomplished by Caddick et al (Equation 3).52 
 
Equation 3.  
 
  
The Mizoroki-Heck cyclization is an attractive strategy for constructing the guaipyridine 
core of cananodine and all members of the rupestine family. This reaction contributes to the 
practicality of the total synthesis of rupestines B (1.16) and C (1.17), allowing for the application 
of commercial viability. Not only are the diastereomers separable by MPLC, but the synthesis 
involves only six steps, making it a much more selective and efficient synthesis when compared 
to the previous syntheses of guaipyridine alkaloids. This straightforward approach could allow for 
preparation of sufficient quantities of rupestines B and C for biological testing, potentially leading 
















Cs2CO3 (1.5 equiv.), DMA, 140 ºC








4. Exploratory Synthetic Studies 
4.1. Studies toward the synthesis of rupestines L and M 
 To access rupestines L (1.25) and M (1.26), we planned to form the target compounds as a 
mixture of diastereomers to be separated in the final step, similar to our synthesis of rupestines B 
and C. Rupestines L and M would be accessed through a reduction of ketone 4.1 to the secondary 
alcohol followed by a hydrogenation of the conjugated 1,1-disubstituted alkene (Scheme 16). The 
guaipyridine core of ketone 4.1 would again be accessed through an intramolecular Mizoroki-Heck 
reaction. To set the stage for the cyclization, the nitro group of intermediate 4.2 would first be 
converted to a carbonyl followed by deallylation and triflation of the phenolic hydroxyl. 
Intermediate 4.2 can be formed with picolyl bromide 2.4 and 5-nitro-1-pentene (4.3) through 
alkylation.  
 


























To access rupestines L and M, our proposed synthesis began with an alkylation of picolyl 
bromide 2.4 with 5-nitro-1-pentene (4.3) using Watson’s procedure53 to give nitro 4.2 (Scheme 
17). The desired product 4.2 and picolyl bromide have identical Rf values, making it impossible to 
isolate the product without any unreacted picolyl bromide. By refluxing in dioxane for five days, 
GC-MS (gas chromatography-mass spectrometry) confirmed the consumption of picolyl bromide 
and purification by flash column chromatography afforded the product in a 27% yield. In our first 
attempts to alkylate 5-nitro-1-pentene (4.3) with picolyl bromide 2.4, we used our original 
alkylation conditions of K2CO3 in acetone. Unfortunately, these conditions provided only trace 
amounts of desired product 4.2. After success using Watson’s procedure, we determined the more 
exotic conditions were necessary in providing alkylated nitro compound 4.2 due to the high 
stability of the resulting anion of 5-nitro-1-pentene (4.3), making it a poor nucleophile. A Nef 
reaction54 on the nitro group of 4.2 would provide ketone 4.4 followed by deallylation and triflation 
of the corresponding hydroxyl to give triflate 4.5. An intramolecular Mizoroki-Heck reaction 
would provide the bicyclic guaipyridine core of ketone 4.1. Enantioselective reduction of the 
ketone, using a ruthenium chiral diamine transfer hydrogenation system by Noyori,55 would 
provide alcohol 4.6. An alternative method to reducing the ketone is by carrot root (Daucus carota) 
via a chemoenzymatic reduction.56 A hydroxyl directed hydrogenation of alcohol 4.6 can then be 















4.2. Studies toward the synthesis of optically active cananodine  
To isolate optically active cananodine (1.6) we envisioned a path where we could obtain 
rupestine G (1.20) and its epimer and methylate the trans isomer to obtain cananodine and 
rupestine D (1.18). Rupestine G and its epimer would be accessed from 4.7 by hydrogenation of 
the conjugated 1,1-disubstituted alkene (Scheme 18). The methyl ester of 4.7 would be formed by 
oxidation of the primary alcohol of intermediate 4.8. The guaipyridine core of intermediate 4.7 
would be formed through an intramolecular Mizoroki-Heck reaction following the deallylation 
and triflation of alcohol 4.8. Through alkylation of oxazolidinone 4.9 with picolyl bromide 2.4, 






























































Scheme 18. Retrosynthetic analysis of optically active cananodine.  
 
 
To access enantiomerically pure cananodine, our synthesis begins with an Evans 
alkylation59 of oxazolidinone 4.9 with picolyl bromide 2.4 to provide intermediate 4.10 as a single 
diastereomer (Scheme 19). Cleavage of the chiral auxiliary with lithium borohydride provides 
primary alcohol 4.8 in a 50% yield.60 Purification of alcohol 4.8 is difficult as the cleaved auxiliary 
and alcohol 4.8 have similar Rf values. By repeated radial chromatography, the two compounds 
can be separated in small batches. The original proposed route to obtaining methyl ester 4.11 was 
exposure of alcohol 4.8 to oxidizing agent pyridinium dichromate (PDC) in MeOH.61 
Unfortunately, this did not oxidize the alcohol to either the methyl ester nor the acid and unreacted 
starting material was obtained. We hypothesized that the alcohol could be oxidized to the 
carboxylic acid with PDC in CH2Cl2 and when consumption of the alcohol was confirmed, MeOH 
could be added to subsequently convert the acid to the methyl ester. This method was unsuccessful 
and results by data analysis are unclear as no unreacted starting material was recovered. A Swern 



























to the methyl ester. Recent 1H NMR analysis of the Swern oxidation has confirmed the presence 
of an aldehyde. An alternate route for accessing the methyl ester of compound 4.11 could be 
through the use of a thiazolidinethione which could be esterified directly to the methyl ester.63 
Once the methyl ester is isolated, deprotection, triflation and Mizoroki-Heck cyclization will 
provide ester 4.7. Hydrogenation of ester 4.7 will give optically active rupestine G (1.20) and its 
diastereomer (4.13). The trans isomer will be methylated to provide optically pure (+)-cananodine 
(1.6) and rupestine D (1.18). (-)-Cananodine (1.62) can also be isolated by methylating rupestine 




































































































In summary, rupestines B and C were synthesized by implementing an intramolecular 
Mizoroki-Heck cyclization strategy to construct the guaipyridine core. Although the 
hydrogenation step was not highly selective, the diastereomers were separable by reverse-phase 
chromatography. Overall, rupestines B (1.16) and C (1.17) were isolated in six steps in total yields 
of 9% and 18%, respectively.  
Although the alkylation step with 4-iodo-1-butene (2.6) to provide intermediate 3.2 was 
not high yielding, the other steps in the total synthesis are all nearly quantitative, with exception 
of the Heck cyclization step. While the Mizoroki-Heck cyclization provides a moderate yield, it 
still shows significant improvement over previous routes to accessing the bicyclic guaipyridine 
core such as the epoxide-opening cyclization route. With this successful method in hand, other 
members of the rupestine family could be isolated and transformations at the 8-position could 














6. Experimental Section 
 
General Experimental Procedures 
 
All reactions involving air sensitive materials were carried out in oven-dried glassware 
under an argon atmosphere. 1,4-Dioxane was purchased in anhydrous form from Alfa Aesar and 
used as received. Other solvents were dried either by passing the solvent through a column of 
activated alumina using an Innovative Technology Pure-SolvTM 400 Solvent Purification System 
(Et2O, THF, CH2Cl2). 
In all procedures, after extractive work-up with the solvents and solutions indicated, the 
combined organic solution washed with brine, dried (Na2SO4 or MgSO4), filtered, and the solvent 
removed by rotary evaporation unless otherwise indicated. All chromatography was performed 
with mixtures of hexanes and ethyl acetate unless otherwise noted. Flash chromatography was 
carried out on hand-packed columns of silica gel (230-400 mesh). Reverse phase chromatography 
was performed on a CombiFlash Rf Teledyne Isco automated column. The reverse-phase columns 
used were RediSep Rf (20-40 µm, 100Å, 5.5 g media) from Teledyne Isco. All TLC plates were 
run on Silicycle 0.25 mm silica layer fluorescence UV254 plates. 
Infrared spectra (IR) were recorded on either an ATI Mattson Genesis Series FT-IR or 
ThermoNicolet iS10 FT-IR Spectrophotometer (Diamond ATR) spectrometer. All absorptions are 
reported in cm-1. Spectra were often recorded as films deposited from CDCl3 (dep. CDCl3) or 
CH2Cl2 (dep. CH2Cl2) followed by solvent evaporation. 
1H and 13C NMR spectra were collected on a Varian Mercury (300 MHz) or a Varian 
UNITYInova (500 MHz) spectrometer and processed with MestreNova software. All chemical shifts 
are reported in ppm and all coupling constants are reported in Hertz. 1H NMR spectra in CDCl3 




acetone at 2.17 ppm and are reported using the following format: chemical shift [multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant(s) (J in Hz), integral]. 
















































Notebook Entry: ESSB82 
K2CO3 (2.70 g, 19.2 mmol) was added to a 2-neck 100 mL round bottom flask equipped with a stir 
bar and reflux condenser. The flask was purged with argon and dry acetone (50 mL) was added. 
Keto ester 2.3 (1.07 mL, 8.63 mmol) was added dropwise followed by picolyl bromide 2.4 (2.00 
g, 8.25 mmol) and the reaction was brought to reflux. After 3 hours, TLC showed unreacted 
starting material so excess K2CO3 (1.35 g, 9.77 mmol) was added and the reaction was left to 
reflux overnight. The next morning, the reaction had turned a beige milky color. The crude mixture 
was vacuum filtered, rinsed with acetone and concentrated via rotary evaporation. The mixture 
was then purified by flash column chromatography in hexanes : ethyl acetate (6:1) to give keto 
ester 2.5 as a brown crystalline solid (1.83 g, 6.28 mmol, 76%).  
 
IR: 2951, 1743, 1714, 1648, 1581, 1459, 1435, 1350, 1258, 1240, 1165, 1123, 994, 929, 818, and 
669 cm-1. 
1H NMR (CDCl3, 300 MHz): d 6.94 (d, J = 8.3, 1H), 6.87 (d, J = 8.3, 1H), 6.02 (m, 1H), 5.40 (dq, 
J =17.3, 1.6, 1H), 5.28 (dq, J = 10.5, 1.4, 1H), 4.51 (dt, J = 5.1, 1.6, 2H), 4.30 (m, 1H), 3.72 (s, 
3H), 3.57-3.29 (m, 2H), 2.79 (qd, J = 7.2, 1.2, 2H), 2.37 (s, 3H), and 1.09 (t, J = 7.2, 3H).  
13C NMR (CDCl3, 75 MHz): d 206.3, 170.6, 150.3, 148.3, 146.9, 132.9, 121.0, 118.4, 117.6, 68.9, 
55.2, 52.3, 36.3, 30.6, 23.1 and 7.6.  






















Notebook Entry: ESSB39, ESSB40 
To a 200 mL round bottom flask equipped with a stir bar, triphenylphosphine (15.7 g, 60.0 mmol), 
and imidazole (4.08 g, 60.0 mmol) were added. CH2Cl2 (100 mL) was added and the solution was 
cooled to 0° C in an ice bath. Iodine (15.2 g, 60.0 mmol) was added slowly (exothermic) and left 
to stir for 15 minutes. 3-Buten-1-ol (4.90 mL, 57.0 mmol) was added slowly with the solution 
remaining in the ice bath and then the mixture was warmed to room temp. After 3 hours, CH2Cl2 
was removed by distillation and replaced by pentane. The suspension was filtered through Celite 
and the filtrate was decanted away from any recrystallized PPh3. The solution was concentrated 
via distillation to afford iodide 2.6 as a clear yellow liquid. (4.15 g, 22.8 mmol, 40%).  
 
IR: 3079, 2978, 2958, 1638, 1425, 1303, 1246, and 1168 cm-1.  
1H NMR (CDCl3, 300 MHz): d 5.75 (m, 1H), 5.15 (s, 1H), 5.10 (d, J = 5.1, 1H), 3.19 (t, J = 7.2, 
2H), and 2.62 (q, J = 7.0, 2H). 























Notebook Entry: ESSC24 
 
A 10 mL 2-neck round bottom equipped with a stir bar and reflux condenser was charged with dry 
THF (5 mL) and DMPU (1 mL) and purged with argon. Solution was cooled to -78 ºC and LHMDS 
(0.040 mL, 0.20 mmol) was added, followed by keto ester 2.5 (0.060 g, 0.20 mmol) added 
dropwise. After 30 min, iodide 2.6 (0.037 g, 0.20 mmol) was added dropwise and the reaction was 
left to warm to room temperature overnight. After 24 hours, the solution was brought to reflux. 
After another 24 hours, the reaction was quenched with water and transferred to a separatory funnel 
and extracted with ethyl acetate. Organic layer was dried over Na2SO4 and concentrated via rotary 
evaporation. The crude material was purified by flash column chromatography in hexanes : ethyl 
acetate (6:1) to give substituted keto ester 2.2 as a dark yellow oil (0.041 g, 0.12 mmol, 60%).  
 
IR: 3078, 2977, 2939, 1741, 1712, 1641, 1580, 1257, 1200, 1168, 1126, 1020, 994, 916, and 816 
cm-1. 
1H NMR (CDCl3, 300 MHz): d 6.96 (d, J = 8.3, 1H), 6.85 (d, J = 8.4, 1H), 6.01 (ddt, J = 17.3, 
10.4, 5.2, 1H), 5.69 (m, 1H), 5.37 (dq, J = 17.3, 1.6, 1H), 5.28 (dq, J = 10.5, 1.4, 1H), 4.91 (m, 
2H), 4.48 (dt, J = 5.2, 1.6, 2H), 3.72 (s, 3H), 3.50 (d, J = 10.0, 1H), 3.50 (d, J = 10.0, 1H) 2.83-
2.52 (m, 3H), 2.33 (s, 3H), 2.00-1.84 (m, 4H), and 1.09 (t, J = 7.2, 3H).  
13C NMR (CDCl3, 75 MHz): d 138.0, 132.9, 121.1, 118.8, 117.8, 114.6, 69.1, 62.5, 52.1, 33.0, 
32.4, 31.2, 28.5, 23.0 and 8.1. 






















Notebook Entry: ESSB94 
A 100 mL 2-neck round bottom equipped with a stir bar and reflux condenser was charged with t-
BuOK (0.44 g, 3.9 mmol) and purged with argon. Keto ester 2.5 (0.59 g, 2.0 mmol) dissolved in 
THF (30 mL) was added to the flask and the reaction was brought to reflux. After 1 hour, tosylate 
2.7 (0.88 g, 3.9 mmol) in THF was added dropwise and the reaction was left to reflux overnight. 
The reaction was quenched with water and transferred to a separatory funnel and extracted with 
ethyl acetate. The organic layer was dried over Na2SO4 and concentrated via rotary evaporation. 
The crude material was purified by flash column chromatography in hexanes : ethyl acetate (6:1) 
to give substituted keto ester 2.2 as a yellow oil (0.21 g, 0.60 mmol, 30%).  




























Notebook Entry: ESSC158 
A 25 mL 2-neck round bottom was equipped with a stir bar and charged with Pd(PPh3)4 (9.0 mg, 
0.0077 mmol) and K2CO3 (20 mg, 0.15 mmol). The flask was purged with argon and substituted 
keto ester 2.2 (20 mg, 0.058 mmol) diluted in MeOH (2 mL) was added to the flask in an ice bath 
and the reaction was left overnight. The solution was quenched with water and transferred to a 
separatory funnel. The organic layer was extracted with ethyl acetate and washed with brine. The 
combined organic layers were dried over Na2SO4 and concentrated via rotary evaporation. The 
crude mixture was purified by flash column chromatography in hexanes : ethyl acetate (3:1) to 
give alcohol 2.8 as a yellow oil (6.2 mg, 0.025 mmol, 43%). 
 
IR: 3076, 2949, 2927, 2575(br), 1732, 1641, 1578, 1279, 1163, 909, 828, and 730 cm-1 
1H NMR (CDCl3, 300 MHz): d 7.05 (d, J = 8.2 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 5.76 (ddt, J = 
17.0, 10.0, 6.5 Hz, 1H), 5.06-4.90 (m, 2H), 3.66 (s, 3H), 3.21 (dd, J = 13.5, 9.5 Hz, 1H), 3.08-2.94 
(m, 1H), 2.86 (dd, J = 13.5, 4.5 Hz, 1H), 2.41 (s, 3H), 2.21-1.99 (m, 2H), and 1.90-1.65 (m, 2H). 
13C NMR (CDCl3, 75 MHz): d 178.2, 149.0, 148.9, 146.3, 137.6, 124.6, 122.3, 115.1, 52.0, 44.7, 
33.8, 32.1, 31.0, and 23.0. 



















Notebook Entry: ESSB133, ESSB134 
A 50 mL 2-neck round bottom flask flushed with argon was charged with sodium hydride (60% 
dispersion in mineral oil, 0.10 g, 2.5 mmol). DMF (15 mL) was added and the solution was cooled 
to 0 °C. A solution of diol 2.14 (0.28 g, 2.0 mmol) in DMF was added and the reaction was left at 
room temp for one hour. Reaction was cooled to 0 °C again and methyl ether 2.15 (0.20 g, 2.5 
mmol) was added slowly and the ice bath was removed and the reaction was left overnight. The 
reaction was quenched with water and transferred to a separatory funnel, washed with a LiCl 
solution and extracted with diethyl ether. The organic layers were dried over Na2SO4 and 
concentrated via rotary evaporation. The crude material was purified by flash column 
chromatography in hexanes : ethyl acetate (1:1) to give alcohol 2.16 as a yellow oil (0.21 g, 1.12 
mmol, 56%). 
 
IR: 3397, 2904, 1582, 1467, 1406, 1311, 1253, 1206, 1153, 1124, 1080, 1051, 980, 922, and 825 
cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.30 (d, J = 8.2, 1H), 7.00 (d, J = 8.3, 2H), 5.19 (s, 2H), 4.72 (s, 
2H), 3.46 (s, 3H), and 2.50 (s, 3H).  























Notebook Entry: ESSB136, ESSB139 
PPh3 (0.720 g, 2.73 mmol) was added to a 100 mL two-neck round bottom flask equipped with a 
stir bar and flushed with argon. Alcohol 2.16 (0.500 g, 2.73 mmol) was diluted in dry CH2Cl2 (30 
mL) and added to the flask and the solution was cooled to -78 °C. N-Bromosuccinimide (0.486 g, 
2.73 mmol) was added slowly over 30 minutes and the dry ice bath was removed and reaction was 
left overnight. The solution was transferred to a separatory funnel and extracted with ethyl acetate 
and washed with NaHCO3, brine, and water. The organic layers were dried over Na2SO4 and 
concentrated via rotary evaporation to give a light pink slush. The crude mixture was purified by 
flash column chromatography in hexanes : ethyl acetate (2:1) to give bromide 2.17 as a yellow oil 
that becomes a pink solid (0.537 g, 2.18 mmol, 80%).  
 
IR: 2925, 1576, 1468, 1254, 1212, 1160, 1143, 1079, 984, and 938 cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.33 (d, J = 8.2, 1H), 7.04 (d, J = 8.4, 1H), 5.25 (s, 2H), 4.62 (s, 
2H), 3.51 (s, 3H), and 2.49 (s, 3H).  
























Notebook Entry: ESSB141, ESSC31 
K2CO3 (0.228 g, 1.65 mmol) was added to a 2-neck 100 mL round bottom flask equipped with a 
stir bar and reflux condenser. The flask was purged with argon and dry acetone (10 mL) was added. 
Keto ester 2.3 (0.250 mL, 2.00 mmol) was added dropwise followed by bromide 2.17 (0.406 g, 
1.65 mmol) and the reaction was brought to reflux and left overnight. The crude mixture was 
vacuum filtered, rinsed with acetone and concentrated via rotary evaporation. The crude material 
was then purified by flash column chromatography in hexanes : ethyl acetate (6:1 then 3:1) to give 
keto ester 2.18 as a yellow oil (0.419 g, 1.42 mmol, 86%).  
 
IR: 2952, 1744, 1716, 1465, 1351, 1253, 1154, 1120, 1078, 988, 824, and 666 cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.34 (d, J = 8.5, 1H), 7.05 (d, J = 8.5, 1H), 5.25 (s, 2H), and 4.62 
(s, 2H), 3.51 (s, 3H), 3.46 (s, 3H), 2.57 (q, J = 7.3, 3H), 2.49 (s, 3H), and 1.09 (t, J = 7.3, 3H).  
13C NMR (CDCl3, 75 MHz): d 206.29, 170.51, 149.62, 148.99, 147.05, 121.19, 121.02, 94.42, 































Notebook Entry: ESSC24, ESSC30, ESSC46, ESSC50 
A 2-neck 25 mL round bottom equipped with a stir bar and reflux condenser was purged with 
argon and charged with THF (5 mL) and DMPU (1 mL). The solution was cooled to -60 °C 
(MeOH/CO2) and LHMDS was added (0.040 mL, 0.20 mmol). Keto ester 2.18 (60 mg, 0.20 mmol) 
was diluted in THF and added to the flask dropwise. The flask was left in the ice bath for one hour 
and then iodide 2.6 (0.37 mg, 0.20 mmol) in THF was added dropwise. The reaction flask was left 
in the ice bath and allowed to warm to room temperature overnight. In the morning, the reaction 
was brought to reflux. After 5 hours, the solution was cooled and THF was removed by rotary 
evaporation. The crude mixture was dissolved in ethyl acetate and transferred to a separatory 
funnel and washed with NH4Cl and brine then dried over Na2SO4. The solution was concentrated 
via rotary evaporation to give a yellow oil then purified by flash column chromatography in 
hexanes : ethyl acetate (6:1/3:1) to give substituted keto ester 2.19 as a yellow oil (42 mg, 0.12 
mmol, 60%).  
 
IR: 2949, 1742, 1713, 1641, 1580, 1465, 1408, 1375, 1346, 1251, 1201, 1154, 1111, 1078, 990, 


















1H NMR (CDCl3, 300 MHz): d 7.24 (d, J = 8.3, 1H), 6.86 (d, J = 8.4, 1H), 5.70 (m, 1H), 5.13 (s, 
2H), 4.92-4.88 (m, 2H), 3.73 (s, 3H), 3.51, (dd, J = 6.3, 9.2, 2H), 3.42 (s, 3H), 3.06 (s, 3H), 1.98 
(m, 4H), and 1.10 (t, J = 7.2, 3H).  
13C NMR (CDCl3, 75 MHz): d 208.04, 173.15, 149.77, 149.53, 146.26, 137.88, 121.46, 121.32, 










































Notebook Entry: ESSC208, ESSC250 
In a culture tube equipped with a stir bar, p-TSA (0.182 g, 0.956 mmol) was added followed by 
keto ester 2.3 (1.00 mL, 7.97 mmol,) and allyl alcohol (2.70 mL, 39.8 mmol). The reaction was 
left to stir at room temperature for 24 hours. TLC showed unreacted ester so an additional 
equivalent of p-TSA was added and the solution was left to stir for another 24 hours. The solution 
was then diluted in ether and transferred to a separatory funnel and washed with NaHCO3 and 
brine. The combined organic layers were dried over Na2SO4 and concentrated via rotary 
evaporation to give a clear colorless oil. The crude material was purified by flash column 
chromatography in hexanes : ethyl acetate (6:1/3:1) to give allyl keto ester 3.1 as a clear colorless 
oil (0.647 g, 4.14 mmol, 52%). 
 
IR: 2981, 2942, 1740, 1713, 1649, 1458, 1412, 1358, 1307, 1274, 1241, 1155, 1106, 1060, and 
984 cm-1. 
1H NMR (CDCl3, 300 MHz): d 5.95 (ddt, J = 17.2, 10.4, 5.8, 1H), 5.35 (dq, J = 17.2, 1.5, 1H), 
5.25 (dq, J = 10.4, 1.3, 1H), 4.64 (dt, J = 5.8, 1.4, 2H), 3.48 (s, 2H), 2.58 (q, J = 7.3, 2H), and 1.09 
(t, J = 7.3, 3H). 


























Notebook Entry: ESSC214, ESSC228, ESSC254 
K2CO3 (0.803 g, 5.81 mmol) was added to a culture tube equipped with a stir bar and purged with 
argon. Acetone (25 mL) was added followed by allyl keto ester 3.1 (0.412 g, 2.64 mmol) in acetone 
added dropwise. Picolyl bromide 2.4 (0.640 g, 2.64 mmol) was added and the solution was brought 
to reflux and left overnight. After 24 hours, the solution was cooled and vacuum filtered. The crude 
mixture was isolated via rotary evaporation to give a yellow oil which was purified by flash column 
chromatography in hexanes : ethyl acetate (6:1) to give allyl keto ester 3.4 as a yellow oil (0.821 
g, 2.59 mmol, 98%). 
 
IR: 2979, 2939, 1741, 1713, 1649, 1581, 1459, 1424, 1411, 1350, 1258, 1239, 1162, 1122, 1060, 
992, 924, and 816 cm-1. 
1H NMR (CDCl3, 300 MHz): d 6.94 (d, J = 8.3, 1H), 6.87 (d, J = 8.3, 1H), 6.11-5.79 (m, 2H), 
5.40 (dq, J = 17.3, 1.6, 1H), 5.31 (dq, J = 8.2, 1.5, 1H), 5.28-5.20 (m, 2H), 4.65-4.60 (m, 2H), 4.51 
(dt, J = 5.1, 1.6, 2H), 4.34 (dd, J = 8.9, 6.1, 1H), 3.51 (dd, J = 17.0, 8.9, 1H), 3.36 (dd, J = 17.0, 
6.0, 1H), 2.79 (q, J = 7.3, 2H), 2.37 (s, 3H), and 1.09 (t, J = 7.2, 3H). 
13C NMR (CDCl3, 75 MHz): d 206.2, 169.7, 150.3, 148.4, 146.9, 132.9, 131.8, 121.0, 118.4, 118.3, 
117.6, 68.9, 66.7, 36.3, 30.5, 23.1 and 7.7. 























Notebook Entry: ESSC226, ESSC236 
A culture tube equipped with a stir bar was purged with argon and charged with dry THF (5 mL) 
and DMPU (1 mL). The solution was cooled to -60 °C (MeOH/CO2) and LHMDS was added 
dropwise (0.060 mL, 0.32 mmol). Allyl keto ester 3.4 (0.10 g, 0.32 mmol) was diluted in THF and 
added to the flask dropwise. The reaction flask was left in the ice bath for one hour and then iodide 
2.6 (0.060 g, 0.32 mmol) in THF was added dropwise. The reaction flask was left in the ice bath 
and allowed to warm to room temperature overnight. In the morning, the reaction was heated and 
left refluxing for 5 hours, turning a dark auburn color. The solution was cooled and THF was 
removed by rotary evaporation. The crude material was dissolved in ethyl acetate and transferred 
to a separatory funnel, washed with NH4Cl and brine, then dried over Na2SO4. The solution was 
concentrated to give a yellow oil then purified by flash column chromatography in hexanes : ethyl 
acetate (6:1/3:1) to give substituted keto ester 3.2 as a yellow oil (0.052 g, 0.18 mmol, 57%). 
 
IR: 3080, 2925, 1711, 1700, 1641, 1580, 1460, 1424, 1376, 1346, 1257, 1239, 1220, 1191, 1167, 
1123, 1018, 992, 914, 815 and 732 cm-1. 
1H NMR (CDCl3, 300 MHz): d 6.94 (d, J = 8.4, 1H), 6.84 (d, J = 8.4, 1H), 6.07-5.80 (m, 2H), 
5.78-5.62 (m, 1H), 5.37 (dq, J = 17.3, 1.6, 1H), 5.30 (dq, J = 4.4, 1.4, 1H), 5.27-5.16 (m, 2H), 
5.01-4.79 (m, 2H), 4.69-4.52 (m, 2H), 4.47 (dt, J = 5.1, 1.5, 2H), 3.51 (q, J = 5.3, 2H), 2.86-2.53 

















13C NMR (CDCl3, 75 MHz): d 208.0, 172.3, 150.7, 148.5, 146.2, 138.0, 132.9, 131.9, 121.1, 118.1, 
118.4, 117.7, 114.6, 69.0, 65.6, 62.5, 33.2, 32.5, 31.4, 28.5, 23.0 and 8.1.  


















































Notebook Entry: ESSC234, ESSC238, ESSC248, ESSC258 
A culture tube equipped with a stir bar was charged with K2CO3 (0.156 g, 1.13 mmol) and 
Pd(PPh3)4 (0.0507 g, 0.0439 mmol) and then purged with argon. Methanol (7 mL) was added 
followed by substituted keto ester 3.2 (0.163 g, 0.439 mmol) in methanol and added dropwise. The 
solution was left stirring at room temperature for 4 hours, turning a cloudy yellow color. The 
solution was concentrated via rotary evaporation and then diluted in CH2Cl2 and transferred to a 
separatory funnel. The organic layer was washed with NH4Cl and brine. Combined organic layers 
were dried over Na2SO4 and concentrated via rotary evaporation to give a yellow solid. The crude 
material was purified by flash column chromatography in hexanes : ethyl acetate (2:1) to give 
alcohol 3.5 as a white crystalline solid (0.105 g, 0.426 mmol, 97%). 
 
IR: 3391, 2973, 2924, 1700, 1640, 1579, 1473, 1376, 1334, 1277, 1258, 1157, 1108, 993, 941, 
909, 825, 730 and 693 cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.03 (d, J = 8.2, 1H), 6.84 (d, J = 8.2, 1H), 5.77 (ddt, J = 16.8, 
10.2, 6.5, 1H), 5.10-4.92 (m, 2H), 3.23-3.17 (m, 2H), 2.82-2.53 (m, 4H), 2.16 (s, 3H), 2.11-1.62 
(m, 6H), and 0.96 (t, J = 7.2, 3H). 
13C NMR (CDCl3, 75 MHz): d 217.8, 148.5, 146.5, 137.6, 124.7, 122.2, 122.0, 115.4, 51.2, 35.5, 
32.7, 31.8, 30.9, 23.2 and 7.7. 



















Notebook Entry: ESSC240, ESSC261 
A culture tube equipped with a stir bar was charged with PhNTf2 (35 mg, 0.10 mmol, 1.2 eq) and 
purged with argon. Alcohol 3.5 (21 mg, 0.085 mmol) was dissolved in dry CH2Cl2 (1 mL) and 
added to the flask. Triethylamine (0.014 mL, 0.10 mmol) was added and the solution was left 
stirring at room temperature overnight. The next morning, the solution was diluted in ether and 
transferred to a separatory funnel to be washed with 10% NaOH, NH4Cl, and brine. The organic 
layers were dried over Na2SO4 and concentrated via rotary evaporation to give a white solid. The 
crude material was purified by flash column chromatography in hexanes : ethyl acetate (12:1) to 
give triflate 3.3 as a yellow oil (0.031 g, 0.082 mmol, 97%). 
 
IR: 2938, 1712, 1595, 1457, 1424, 1377, 1250, 1209, 1138, 1076, 914, 873, and 703 cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.41 (d, J = 8.4, 1H), 7.03 (d, J = 8.4, 1H), 5.78 (ddt, J = 16.8, 
10.2, 6.5, 1H), 5.09-4.95 (m, 2H), 3.35-3.19 (m, 3H), 2.94 (q, J = 11.8, 2H), 2.75-2.52 (m, 3H), 
2.48 (s, 3H), 2.09 (q, J = 7.4, 2H), 1.77 (dq, J = 15.0, 8.3, 7.5, 1H), 1.58 (tq, J = 13.6, 6.4, 1H) and 
1.05 (t, J = 7.3, 3H). 
13C NMR (CDCl3, 75 MHz): d 214.0, 157.6, 151.5, 143.1, 137.6, 128.8, 122.0, 115.3, 48.0, 36.0, 
33.3, 31.3, 31.1, 23.8 and 7.6. 




















Notebook Entry: ESSC264 
A culture tube equipped with a stir bar was charged with Pd(PPh3)4 (0.0276 g, 0.0319 mmol) and 
K2CO3 (0.127 g, 0.920 mmol). The culture tube was purged with argon and dioxane (3 mL) was 
added. Triflate 3.3 (0.0701 g, 0.184 mmol) in dioxane was added and the reaction was left heating 
overnight at 130 °C. After 48 hours, the solution was removed from heat and left to cool. The 
solution was diluted with ethyl acetate and filtered through a silica gel pipette. The crude material 
was purified by flash column chromatography in hexanes : ethyl acetate (2:1) to give cycloheptane 
3.6 as a yellow oil (0.0270 g, 0.118 mmol, 64%). 
 
IR: 2935, 1708, 1630, 1588, 1560, 1460, 1411, 1390, 1373, 1114, 1084, 1054, 904, and 831 cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.38 (d, J = 7.7, 1H), 6.96 (d, J = 7.7, 1H), 5.15 (s, 1H), 5.04 (s, 
1H), 3.09 (d, J = 6.5, 2H), 2.85-2.74 (m, 1H), 2.70-2.55 (m, 2H), 2.54 (dd, J = 7.3, 2.2, 1H), 2.49 
(s, 3H), 2.36-2.23 (m, 1H), 2.05-1.83 (m, 2H) and 1.04 (t, J = 7.3, 3H).  
13C NMR (CDCl3, 75 MHz): d 213.1, 156.4, 148.4, 136.0, 135.3, 121.3, 115.4, 48.4, 39.9, 34.2, 
33.8, 32.2, 24.1 and 7.8. 

























Notebook Entry: ESSC266, ESSD38, ESSD58, ESSD74 
A 25-mL two neck round bottom equipped with a stir bar was charged with alkene 3.6 (91.0 mg, 
0.397 mmol) in methanol (10 mL) and Pd/C (39.0 mg, 10% w/w). The flask was swept with argon 
then flushed with a H2 balloon. The flask was left with balloon pressure H2 overnight. The next 
morning, the flask was purged again with argon and opened to the atmosphere. The black solution 
was diluted in ethyl acetate and filtered through a Celite plug. The product mixture was isolated 
via rotary evaporation as a yellow oil (0.0910 mg, 100%). The diastereomers were isolated via 
reverse-phase column chromatography in 30-80% aqueous methanol. A 36 mg sample of a mixture 
of diastereomers (1:2 rupestine B : rupestine C) was loaded onto 0.36 g of Celite and charged to 
the reverse-phase column. The flow rate was 18 mL/min and the % MeOH began at 30% and was 
gradually increased to 80% over 20 minutes. Pure 1.16 (13 mg) and pure 1.17 (7 mg) were isolated 
as well as 16 mg of the remaining mixture. A second separation was run on a mixture primarily 





















IR: 2962, 2922, 1708, 1590, 1574, 1460, 142, 1375, 1348, 1280, 1164, 1110, 1026, 987, 972, 923, 
825, 772, 731, and 690 cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.36 (d, J = 7.9, 1H), 6.97 (d, J = 7.9, 1H), 3.24 (dd, J =14.0, 10.8, 
1H), 3.06 (dt, J = 14.0, 1.9, 1H), 3.01-2.93 (m, 1H), 2.59-2.47 (m, 1H), 2.53 (q, J = 7.3, 2H), 2.49 
(s, 3H), 2.05-1.97 (m, 1H), 1.93-1.85 (m, 2H), 1.33 (d, J = 7.0, 3H), 1.29-1.22 (m, 1H), and 1.05 
(t, J = 7.3, 3H).  
13C NMR (CDCl3, 75 MHz): d 213.7, 159.4, 154.4, 137.8, 132.3, 121.1, 48.6, 39.9, 35.1, 34.8, 
34.3, 33.2, 23.9, 20.4 and 7.8.  
HRMS (ESI) Calculated for C15H22NO (M+H): 232.1701. Found: 232.1695. 
 
1-((5S*,8R*)-2,5-dimethyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-8-yl)propan-1-one 
IR: 2962, 2922, 1708, 1590, 1574, 1460, 142, 1375, 1348, 1280, 1164, 1110, 1026, 987, 972, 923, 
825, 772, 731, and 690 cm-1.cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.29 (d, J = 7.7, 1H), 6.91 (d, J = 7.7, 1H), 3.36-3.28 (m, 1H), 
3.19 (dd, J = 14.0, 10.8, 1H), 3.04-2.96 (m, 1H), 2.67-2.72 (m, 1H), 2.56 (q, J = 7.3, 2H), 2.46 (s, 
3H), 2.10-1.97 (m, 1H), 1.88-1.72 (m, 3H), 1.30 (d, J = 7.3, 3H), and 1.02 (t, J = 7.3, 3H). 
13C NMR (CDCl3, 75 MHz): d 213.6, 157.8, 154.7, 137.8, 136.3, 121.2, 48.7, 40.0, 37.7, 34.3, 
32.2, 28.3, 23.9, 18.8, and 7.8.  















Notebook Entry: ESSC56, ESSC76 
5-bromo-1-pentene (2.00 mL, 17.0 mmol) was added to a suspension of NaNO2 (1.25 g, 18.7 
mmol) in DMF (35 mL) and stirred at room temperature overnight. The reaction was quenched 
with H2O and extracted with ether and the combined organic layers were washed with sat. LiCl 
and dried over Na2SO4. The crude material was concentrated via rotary evaporation to give a 
yellow oil then purified by flash column chromatography in pentane : ether (5:1) to give nitro 4.3 
as a yellow oil (0.880 g, 7.65 mmol, 45%).  
 
IR: 3073, 2965, 2928, 2870, 2361, 2341, 1641, 1586, 1549, 1459, 1440, 1382, 1309, 1199, and 
1103 cm-1. 
1H NMR (300 MHz, CDCl3): d 5.77 (m, 1H), 5.11 (q, J = 1.5, 1H), 5.09 (dt, J = 1.9, 1.1, 1H), 5.05 
(t, J = 1.3, 1H), 4.39 (t, J = 6.8, 2H), and 2.14 (m, 4H).  





















Notebook Entry: ESSD102 
Toluene (40 mL) and p-TSA (0.116 g, 0.609 mmol, 5 mol %) were added to a 2-neck 100 mL 
round bottom flask equipped with an addition funnel and reflux condenser. 2,6-dimethylaniline 
(1.00 mL, 8.12 mmol) and 2,4-pentanedione (0.417 mL, 4.06 mmol) were added to the flask and 
the addition funnel was plugged with cotton and filled with molecular sieves (4 Å). A needle was 
added to the septum in the reflux condenser to reduce the pressure. The side arm of the additional 
funnel and the flask were wrapped in foil and the solution was brought to reflux. After 24 hours, 
an additional equivalent of p-TSA was added. After two weeks, the reaction was removed from 
heat and diluted in CH2Cl2. The organic layer was washed with Na2CO3 and brine and dried over 
Na2SO4. The crude material was isolated via rotary evaporation to give a dark brown oil. The crude 
material was purified by flash column chromatography in hexanes : ethyl acetate (2:1) to give a 
brown oil (0.796 g, 2.60 mmol, 64%). 
 
IR: 2918, 2854, 1622, 1594, 1550, 1487, 1465, 1436, 1376, 1363, 1278, 1182, 1093, 1027, 811, 
769, and 696 cm-1. 
1H NMR (CDCl3, 300 MHz): d 12.18 (s, 1H), 7.05-6.92 (m, 6H), 4.88 (s, 1H), 2.16 (s, 12H), and 
1.69 (s, 6H). 















Notebook Entry: ESSD134 
A 2-neck 25 mL round bottom flask equipped with a stir bar and reflux condenser was charged 
with picolyl bromide 2.4 (0.242 g, 1.00 mmol, 1 eq), NaOtBu (0.115 g, 1.20 mmol, 1.2 eq), and 
CuBr (0.0287 g, 0.200 mmol, 0.20 eq). The flask was purged with argon and dioxane (10 mL), 
nitro 4.3 (0.144 g, 1.25 mmol, 1.25 eq), and ligand (0.0766 g, 0.250 mmol, 0.25 eq) were added to 
the flask sequentially via syringe. The resulting suspension was heated in a sand bath at 60 °C with 
rapid stirring for five days. The solution was checked by GCMS to confirm the reaction went to 
completion. Solution was removed from heat and left to cool before diluting in ether. The solution 
was washed with NH4Cl and brine then dried over Na2SO4. The crude material was isolated via 
rotary evaporation to give a dark brown oil which was purified by flash column chromatography 
in hexanes : ethyl acetate (6:1/3:1) to give nitro 4.2 as a dark yellow oil (0.0746 g, 0.270 mmol, 
27%).  
 




















1H NMR (CDCl3, 300 MHz): d 7.02 (d, J = 8.4, 1H), 6.95 (d, J = 8.4, 1H), 6.09-5.97 (m, 1H), 
5.80-5.69 (m, 1H), 5.44-5.29 (m, 2H), 5.08-4.99 (m, 2H), 4.52 (dt, J = 5.2, 1.6, 2H), 3.57 (dd, J = 
15.1, 5.7, 1H), 3.20 (dd, J = 15.0, 8.4, 1H), 2.43 (s, 3H), and 2.22-2.08 (m, 4H). 
13C NMR (CDCl3, 75 MHz): d 150.6, 149.4, 144.8, 136.2, 132.6, 122.0, 119.2, 117.8, 116.1, 85.8, 




























Notebook Entry: ESSD110 
A 2-neck 100 mL round bottom flask equipped with a stir bar was purged with argon and charged 
with THF. The solution was cooled to -78 °C and LHMDS (10.4 mL, 10.4 mmol, 1.0 M in THF) 
was added. Chiral auxiliary 4.9 (2.85 g, 10.4 mmol) was added to the basic solution dropwise 
followed by picolyl bromide 2.4 (2.48 g, 10.3 mmol). The reaction was left overnight at room 
temperature and after 24 hours the solution was diluted in ether and washed with NH4Cl and brine. 
The organic layers were dried over Na2SO4 and isolated via rotary evaporation to give an orange 
oil. The crude material was purified by flash column chromatography in hexanes : ethyl acetate 
(6:1/3:1) to give oxazolidinone 4.10 as a viscous yellow oil (2.46 g, 5.66 mmol, 55%). 
 
IR: 2922, 1176, 1735, 1693, 1640, 1581, 1454, 1424, 1384, 1348, 1290, 1256, 1234, 1348, 1290, 
1256, 1238, 1193, 1100, 1047, 1015, 994, 913, 817, 761, 733, and 701 cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.26 (m, 7H), 6.96 (d, J = 8.3, 1H), 6.87 (d, J = 8.3, 1H), 6.07 (m, 
1H), 5.82 (m, 1H), 5.42 (dq, J = 16.8, 10.2, 1H), 5.30 (dq, J = 10.5, 1.5, 1H), 5.02 (dq, J = 17.1, 
1.7, 1H), 4.95 (ddt, J = 10.2, 2.2, 1.3, 1H), 4.67-4.59 (m, 1H), 4.55-4.45 (m, 3H), 3.33 (m, 2H), 
3.15 (dd, J = 3.15, 4.4, 1H), 2.53 (dd, J = 13.2, 10.6, 1H), 2.38 (s, 3H), 2.23-2.15 (m, 2H), 1.94-
1.82 (m, 1H), and 1.78-1.66 (m, 1H). 
13C NMR (CDCl3, 75 MHz): d 176.7, 152.9, 150.6, 148.4, 148.2, 138.2, 136.1, 133.1, 129.3, 128.9, 


























Notebook Entry: ESSD108 
A solution of LiBH4 (0.710 mL, 2.13 mmol, 3M in THF) was added dropwise to a solution of 
oxazolidinone 4.10 (0.185 g, 0.426 mmol) in THF (2.20 mL) and MeOH (0.0900 mL, 2.22 mmol) 
at -78 °C. After 15 minutes, the ice bath was removed and solution was left to warm to room 
temperature overnight. After 24 hours, the reaction mixture was cooled to 0 °C and quenched with 
2M HCl (1.1 mL). The solution was extracted with ether and combined organic layers were washed 
with brine and dried over Na2SO4. Crude material was isolated via rotary evaporation to give a 
white solid. The product was isolated by radial chromatography in ethyl acetate to give alcohol 4.8 
as white crystals (0.0557 g, 0.213 mmol, 50%). 
 
IR: 3363, 3075, 2923, 2856, 1640, 1580, 1458, 1423, 1378, 1258, 1239, 1178, 1132, 1021, 994, 
910, 817, and 768 cm-1. 
1H NMR (CDCl3, 300 MHz): d 7.05 (d, J = 8.4, 1H), 6.93 (d, J = 8.3, 1H), 6.04 (m, 1H), 5.81 (m, 
1H), 5.41 (dq, J = 17.3, 1.6, 1H), 5.31 (dq, J = 10.5, 1.4, 1H), 4.98 (m, 2H), 4.52 (dt, J = 5.2, 1.6, 
2H), 3.50 (m, 2H), 3.00 (m, 2H), 2.44 (s, 3H), 2.10-2.12 (m, 2H), 2.07-1.98 (m, 1H), and 1.53-
1.36 (m, 2H). 
13C NMR (CDCl3, 75 MHz): d 150.8, 149.6, 148.6, 138.9, 132.7, 121.2, 119.6, 117.9, 114.4, 69.1, 
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